Search the Newsreel

Price to earnings forward of AUCyber Limited – ASX:CYB

Revenue Beat: Century Plyboards (India) Limited Beat Analyst Estimates By 8.2%

Immunitybio Inc earnings missed by $0.14, revenue topped estimates

Immunitybio Inc (NASDAQ: IBRX) reported second-quarter EPS of $-0.22, missing analyst estimates by $0.14. However, the company's revenue of $51.24M surpassed the consensus estimate of $47.22M. The stock has seen a significant increase of 196.68% over the last 12 months, despite a recent 7.86% …

ImmunityBio (NASDAQ:IBRX) Shares Gap Down on Disappointing Earnings

IBRX Founder Soon-Shiong Bets On Anktiva's Next Growth Phase — ImmunityBio Posts Record Q2 Sales

ImmunityBio (IBRX) reported record second-quarter revenue of $51.2 million, surpassing Wall Street estimates, largely driven by strong sales of its cancer therapy, Anktiva. Despite a wider net loss due to non-cash accounting charges, Chairman Patrick Soon-Shiong highlighted the company's focus on expanding Anktiva's applications …

ImmunityBio Releases Q2 2026 Financial Results

ImmunityBio, Inc. (IBRX) reported a net loss of $230.4M and a loss per share of $0.22 for Q2 2026, widening from Q2 2025 as the company invests in its immunotherapy platform. Despite increased losses, revenue grew significantly to $51.2M, up 92.0% year-over-year, driven by …

Helus Pharma (Nasdaq: HELP) hires Michael Halstead to steer Phase 3 MDD push

Helus Pharma (operating as Cybin Inc.) has appointed Michael Halstead as its new Chief Executive Officer, effective immediately. This appointment comes as the company advances its HLP003 program into Phase 3 for Major Depressive Disorder, with topline data expected in Q4 2026, and HLP004 …

ImmunityBio, Inc. (IBRX) Q2 2026 Earnings

ImmunityBio, Inc. (IBRX) reported its Q2 2026 earnings, with an EPS of -$0.22 against an estimated -$0.08, and revenue of $51M, exceeding the $50M estimate. The company's ANKTIVA revenue saw a 94% year-over-year increase, marking its eighth consecutive quarter of sequential gains. The EPS …

Earnings Flash (IBRX) ImmunityBio, Inc. Reports Q2 Revenue $51.2M, vs. FactSet Est of $49.7M

ImmunityBio, Inc. (IBRX) reported Q2 revenue of $51.2 million, surpassing the FactSet estimate of $49.7 million. This earnings flash indicates stronger-than-expected revenue performance for the biotechnology company in the second quarter.

ImmunityBio Q2 revenue rises 92% to record $50.7 million

ImmunityBio (IBRX) reported a significant increase in Q2 2026 total revenue, reaching $51.2 million, with net product revenue up 92% year-over-year to a record $50.7 million. The company's ANKTIVA product continues to drive growth, marking its eighth consecutive quarter of sequential revenue increase, and …

Record Q2 revenue and higher net loss at ImmunityBio (NASDAQ: IBRX)

ImmunityBio (NASDAQ: IBRX) reported record Q2 2026 net product revenue of $50.7 million, a 92% year-over-year increase, and $94.8 million for the first half of 2026. Despite this revenue growth, the company experienced a higher GAAP net loss of $230.4 million in Q2 and …

Quantum Cyber (QUCY) awards director 190,840 stock options at 1.1400

Hybrid Financial Services profit falls 21% to ₹58 lakh in Q1FY27

FDA Sets Jan. 6 Target Date for ImmunityBio's ANKTIVA Review

Cyber Media India schedules 44th AGM with remote e-voting window

Hybrid Financial Services FY26 Results: Net profit drops 29% to ₹27.00 lakh

Hybrid Financial Services schedules 39th AGM for September 11

Laurion Capital exits Rallybio (RLYB) position, reports 0% beneficial ownership

Laurion Capital Management LP and its co-managing members, Benjamin Alexander Smith and Janaka Sheehan Maduraperuma, have filed an amended Schedule 13G for Rallybio (RLYB), reporting 0% beneficial ownership of the company's common stock. This filing indicates that Laurion Capital and its associated individuals no …

Hybrid Fin Ser Standalone June 2026 Net Sales at Rs 1.07 crore, up 212.42% Y-o-Y

Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IBRX) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ImmunityBio, Inc. (NASDAQ:IBRX) securities who bought shares prior to January 19, 2026, and continue to hold them. The investigation aims to determine if ImmunityBio and its officers engaged in corporate …

Cybin publishes corporate presentation on development of serotonergic agonists for depression, anxiety

Cybin Inc. published a corporate presentation detailing the development of its serotonergic agonists. The presentation highlights HLP003, an oral drug in Phase 3 for major depressive disorder with FDA Breakthrough Therapy Designation, targeting topline data for Q4 2026. Additionally, HLP004, an intramuscular drug for …

Cyber Media Standalone June 2026 Net Sales at Rs 4.10 crore, up 9.25% Y-o-Y

ImmunityBio (IBRX) Could Be 45% Undervalued On UAE ANKTIVA Approval

ImmunityBio (IBRX) has received marketing authorization for ANKTIVA in the UAE for two cancer indications, expanding its global footprint. Despite a recent share price pullback, the company is considered 45% undervalued, with a fair value of $13 compared to its last close of $7.17. …

Cyber Media FY26 Results: Consolidated net profit turns positive

Rallybio Corporation Revenue Breakdown – NASDAQ:RLYB

Century Plyboards Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

CISO Global Inc (CISO) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of CISO Global Inc (CISO), detailing its current price momentum score, support and resistance levels, and performance based on various technical indicators and moving averages. It highlights that CISO is suitable for range-bound swing trading, with its price …

CISO Global Inc Today's Market Trends | CISO Stock Real-Time Quotes, Trading Strategies & Related Analysis | TradingKey

CISO Global Inc. (CISO) is trading at $0.256, showing a slight increase of 1.63%. The company, which specializes in cybersecurity, compliance, and software, has experienced significant price declines over the past year. Despite its growth phase and high institutional ownership, its stock is considered …

CENTURYPLY: Record revenue and profit growth with margin expansion across key segments

Hybrid Financial Services Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

PT Bank Maybank Indonesia Tbk Reports Earnings Results for the Half Year Ended June 30, 2026

Rallybio Corp (RLYB) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Rallybio Corp (RLYB), noting its current valuation score of 6.53 within the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -11.68 and indicates that relevant data for P/B, P/S, and P/CF ratios have …

IBRX Stock Jumps Overnight: UAE Grants Anktiva Broadest Approval Yet After Founder’s ‘July Birthday News’ Tease

ImmunityBio (IBRX) stock jumped nearly 8% after the UAE granted its cancer immunotherapy, Anktiva, its broadest approval yet for bladder and metastatic lung cancer. This approval covers a wider range of bladder cancer patients than currently allowed in the U.S. and follows founder Patrick …

Rallybio Q1 2026 Earnings: Wider-than-Expected Loss as Development Costs Persist - Geographic Revenue Trends

ImmunityBio receives UAE marketing authorizations for ANKTIVA across NMIBC and NSCLC

ImmunityBio (IBRX) has been granted marketing authorization in the UAE for its cancer drug ANKTIVA for two indications: BCG-unresponsive NMIBC and checkpoint-refractory metastatic NSCLC. This expands ANKTIVA's approvals to 34 countries, with the NMIBC approval being the first worldwide to cover CIS with/without papillary …

ImmunityBio Achieves World's Broadest Bladder Cancer Approval as UAE Green Lights Lead Drug

ImmunityBio's ANKTIVA has received its broadest approval yet in the UAE for non-muscle invasive bladder cancer (NMIBC), covering the entire disease spectrum, and also for metastatic non-small cell lung cancer (NSCLC). This approval marks the fifth jurisdiction to greenlight ANKTIVA, expanding its global reach …